Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pargluva Fluid Retention, Cardiac Risk To Be Central Issues At Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Data showing heart failure rates with 5 mg dose of muraglitazar may be higher than with 30 mg pioglitazone (Lilly/Takeda's Actos) in type 2 diabetes patients will be presented to committee at Sept. 9 review.
Advertisement

Related Content

Bristol/Merck Receive Pargluva "Approvable" Letter
Bristol/Merck Receive Pargluva "Approvable" Letter
Bristol/Merck's Pargluva Combination Use With Sulfonylureas Not Recommended
Bristol/Merck's Pargluva Combination Use With Sulfonylureas Not Recommended
Bristol's Abatacept, Muraglitazar To Go Before Advisory Committees In September
Bristol's Abatacept, Muraglitazar To Go Before Advisory Committees In September

Topics

Advertisement
UsernamePublicRestriction

Register

PS063003

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel